Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tesevatinib + Trastuzumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tesevatinib | KD019|XL647|EXEL 7647|KD 019 | EGFR Inhibitor (Pan) 62 EPHB4 Inhibitor 6 HER2 Inhibitor 42 VEGFR2 Inhibitor 37 VEGFR3 Inhibitor 6 | Tesevatinib (XL647) is an inhibitor of multiple receptor tyrosine kinases, including ERBB2 (HER2), EGFR, VEGFR2 and VEGFR3, and EphB4, potentially resulting in decreased tumor growth and angiogenesis (PMID: 17575237, PMID: 30030583). | |
Trastuzumab | Herceptin | Anti HER2 | HER2 (ERBB2) Antibody 76 | Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02154529 | Phase Ib/II | Tesevatinib + Trastuzumab | Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer | Terminated | USA | 0 |